Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Statement re Second Amendment of Bond Instrument

13 Feb 2026 17:13

RNS Number : 0184T
Ceiba Investments Limited
13 February 2026
 

STATEMENT RE SECOND AMENDMENT OF BOND INSTRUMENT

CEIBA INVESTMENTS LIMITED

 

(TICKER CBA, ISIN: GG00BFMDJH11)

Legal Entity Identifier: 213800XGY151JV5B1E88

 

SECOND AMENDMENT OF BOND INSTRUMENT (22 MARCH 2021)

 

CEIBA Investments Limited, the largest listed foreign investor solely dedicated to investing in Cuba, announces that today it will circulate to the holders (the "Bondholders") of the €25,000,000 senior, unsecured convertible bonds due 2029 issued by the Company on 21 March 2021, as amended by a first amendment agreement on 24 January 2025 (the "First Amendment Agreement") (the "Bonds") seeking their approval to enter into a second amendment agreement (the "Second Amendment Agreement") to amend the original bond instrument dated 22 March 2021 constituting the Bonds (the "Original Bond Instrument"), as amended by the First Amendment Agreement.

 

The circular ("Circular") to Bondholders and the Second Amendment Agreement are attached to this Announcement and can also be accessed via the Company's website www.ceibainvest.com

http://www.rns-pdf.londonstockexchange.com/rns/0184T_1-2026-2-13.pdf

http://www.rns-pdf.londonstockexchange.com/rns/0184T_2-2026-2-13.pdf

 

In RNS Announcement 7758R of 5 February 2026 we announced that during the month of February 2026, in order to avoid a potential event of default under the terms of the Bond Instrument, the Company would discuss with Bondholders a formal proposal to amend some of the terms of the Bond Instrument, including, inter alia, to: i) extend the term of the Bond Instrument by 12 months by deferring each of the four remaining segments (B, C, D and E) by that additional period; ii) allow the Company to issue new ordinary shares at a price per Share that is less than the latest published NAV (as defined in the Articles of Incorporation of the Issuer) per Share at the time of issuance; and iii) allow the Company to sell part of its assets provided that the proceeds of such issuance or sale are applied towards the repayment of Segment B and other Segments that are due payable under the Bond Instrument.

 

Based on the outcome of these discussions, it would now appear that the required qualified majority of Bondholders support the proposal to amend the terms of the Original Bond Instrument, as amended by the First Amendment Agreement executed 24 January 2025, and approve the Second Amendment Agreement.

 

The final terms contained in the Second Amendment Agreement stipulate that the final payment date is extended to 31 March 2030 and that the Company is authorized to sell assets of the Company and issue new ordinary shares in the capital of the Company at such price as the Board of Directors determines from time to time, even at a discount to the net asset value per share. Following the original expiry date of 31 March 2026, the interest rate on the Bonds will increase to 15%.

 

Today, Bondholders will receive the Circular containing the extraordinary resolutions to be proposed seeking the Bondholders approval of the Company's entry into the Amendment Agreement. In order to be passed successfully, the Extraordinary Resolutions require Bondholders together holding at least 60% of the principal amount of the Bonds in issue to vote in favour of the Extraordinary Resolutions on or before 27 February 2026. Subject to and following the successful passing of the Extraordinary Resolutions the Company will thereafter enter into the Second Amendment Agreement amending the terms of the Original Bond Instrument. 

 

John A. Herring

Chairman

 

 

For further information, please contact:

 

Sebastiaan Berger

 

Via NSM Funds Limited 

Singer Capital Markets 

James Maxwell / Patrick Weaver (Corporate Finance) 

Sam Geatrex (Sales) 

 

 

Tel: +44 (0)20 7496 3000

NSM Funds Limited

Tel: +44 (0)1481 743030

 

 

www.ceibainvest.com 

 

END OF ANNOUNCEMENT

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRGPUQUPUPQGMW
12
Date   Source Headline
3rd Jul 20234:41 pmRNSUpdate re Internalisation of Management
28th Jun 20236:16 pmRNSResult of AGM
28th Jun 20236:05 pmRNSNet Asset Value(s)
27th Apr 20234:03 pmRNSAnnual Financial Report - Replacement
27th Apr 20237:00 amRNSInternalisation of Management
27th Apr 20237:00 amRNSAnnual Financial Report
7th Feb 20231:07 pmRNSHolding(s) in Company
14th Dec 20221:14 pmRNSCorrection: Half-year Report
1st Dec 20227:00 amRNSService Providers and Registered Office
30th Nov 202212:22 pmRNSNet Asset Value(s)
28th Sep 20227:00 amRNSHalf-year Report
1st Aug 20224:53 pmRNSAlternative Investment Fund Manager–Change of Name
4th Jul 202210:02 amRNSNet Asset Value(s)
16th Jun 20225:34 pmRNSResult of AGM
25th May 20223:38 pmRNSCorrection: Annual Financial Report
29th Apr 20229:45 amRNSAnnual Financial Report
23rd Feb 20227:00 amRNSNet Asset Value(s)
22nd Feb 20227:00 amRNSTrading Update
19th Jan 20224:48 pmRNSHolding(s) in Company
31st Dec 20211:27 pmRNSHolding(s) in Company
31st Dec 20211:26 pmRNSHolding(s) in Company
26th Nov 20214:34 pmRNSHolding(s) in Company
26th Nov 20213:24 pmRNSHolding(s) in Company
1st Oct 20217:00 amRNSAppointment of Non-Executive Director
28th Sep 20217:00 amRNSHalf-year Report
17th Jun 20212:47 pmRNSResult of AGM
28th Apr 20217:00 amRNSAnnual Financial Report
14th Apr 20217:00 amRNSListing of Convertible Bonds
31st Mar 202112:16 pmRNSTrading Statement
15th Jan 20217:00 amRNSNet Asset Value(s)
16th Dec 20207:00 amRNSTrading Statement
3rd Dec 20204:30 pmRNSResult of Extraordinary Meeting
13th Nov 20207:00 amRNSNotice of EGM
23rd Oct 20207:00 amRNSTrading Statement
9th Oct 20204:59 pmRNSHalf-year Report
29th Sep 20207:00 amRNSHalf-year Report
19th Jun 20204:00 pmRNSResult of AGM
8th Jun 20207:00 amRNSTrading Statement
20th May 20205:40 pmRNSNet Asset Value(s)
28th Apr 20207:00 amRNSAnnual Financial Report
3rd Apr 20207:00 amRNSTrading Statement
3rd Dec 20193:37 pmRNSChange of Auditor
6th Nov 201912:32 pmRNSNet Asset Value(s)
30th Sep 20197:00 amRNSHalf-year Report
18th Jun 20195:27 pmRNSResult of AGM
13th Jun 20194:38 pmRNSHolding(s) in Company
11th Jun 201910:53 amRNSPublication of Supplementary Prospectus
3rd Jun 201912:59 pmRNSTrading Statement
29th May 201911:29 amRNSNet Asset Value(s)
30th Apr 20195:40 pmRNSDividend Declaration
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.